€20 million to boost innovative treatments in Europe
InnovFin, the EU Finance for Innovators, grants a new loan to help develop innovative treatments for infectious diseases such as hepatitis B and tuberculosis as well as for human papillomavirus-induced cancer. "This deal under InnovFin ID once again shows the EU's commitment to addressing major public healthcare challenges", said Carlos Moedas, European Commissioner for Research, Science and Innovation. Read more
Europe as a center for museum agriculture?
There are a large number of disincentives for investment and innovation in the EU including heavy administrative burdens put on innovators, absurdly costly and complicated compliance procedures, and even if you come up with an excellent innovation in agriculture, there are malfunctioning and dysfunctional regulatory systems there to inhibit their uptake. Dr Julian Little, former Chair of the Agricultural Biotechnology Council, wonders whether the European Commission and members of the European Parliament really wanted innovation in agriculture or were happy for the rest of the world to be describing Europe as a very large museum of agriculture. Read more on TradeTalk blog
|
Shire is a global specialty biopharmaceutical company that enables people with life-altering conditions to lead better lives. We focus on developing and delivering innovative medicines for patients with rare diseases and other specialty conditions. Rapid advancements in medical science and technology and our growing understanding of the genetic base of diseases are opening up new avenues for developing targeted biopharmaceuticals that work more precisely and effectively, resulting in improvements in patient outcomes. Shire remains at the forefront of these innovations, and through the ‘Transformations’ joint initiative, the European Policy Centre and Shire are promoting multi-stakeholder policy discussions about the positive impact of pharmaceutical innovation. 
